Licences

To date, MPP has signed agreements with 15 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, two long-acting technologies, two experimental oral antiviral treatments for COVID-19 and 12 COVID-19 technologies.

Negotiating public health-driven licences with patent holders, sublicensing to generic manufacturers and product developers, and supporting access to those treatments in LMICs, are the core work of the Medicines Patent Pool.

Below is an overview of all our licensing and sublicensing agreements. For more information, click on the product, patent holder, generic partner or product developer you are interested in.

PRODUCTS LICENSED

Diseases

Patent Holder

Generic Manufacturers and Other Licensees

Countries

Keyword

News & Press Releases » NIH, News & Press Releases » Press Releases

WHO and MPP announce agreement with NIH for COVID-19 health technologies

12 May 2022

MPP Logo

Subscribe to our Newsletter

Founded & funded by

Unitaid Logo

Other funders